Title:Revealing Insights into Natural Products Against mcr-1-Producing Bacteria
Volume: 22
Issue: 17
Author(s): Ana Beatriz Souza Flor dos Santos, Manuele Figueiredo da Silva, João Xavier de Araújo-Júnior and Edeildo Ferreira da Silva-Júnior *
Affiliation:
- Institute of Chemistry and Biotechnology, Federal University of Alagoas, AC. Simoes Campus, Lourival Melo Mota Avenue 57072-970, Maceio,Brazil
Keywords:
MCR-1, phosphoethanolamine transferase, colistin, natural products, bacterial resistance, polymyxin B.
Abstract:
Bacterial resistance has become a major global concern, affecting about 500, 000 individuals
in 22 countries. Thus, it is clear that Gram-negative bacteria have been receiving more attention
in this scenario. These bacteria perform several resistance mechanisms, such as modifying
lipid A from lipopolysaccharides as a product of the mcr-1 gene expression. This gene was initially
identified in animals; however, it quickly spread to humans, spreading to 70 countries. Mcr-1 gene
attributes resistance to polymyxin B and colistin, which are drugs established as the last alternative
to combat Enterobacteriaceae bacteria.
Notwithstanding the prevalence and lack of antibiotic therapies for such bacteria, this article aimed
to compile information about natural compounds against the resistance attributed by this gene, including
the activity of isolated colistin or its associations with other antibiotics. Among the studies
that evaluated colistin's synergistic action with other compounds, azidothymidine and isoalantholactone
stood out. On the other hand, the paenipeptin 1 analog showed satisfactory activities when associated
with other antibiotics. Besides, it is worth mentioning that molecular docking results between
ostole and eugenol toward phosphoethanolamine transferase MCR-1 revealed that these compounds
could interact with critical amino acid residues for the catalytic action of this enzyme.
Based on this, natural agents' role is evident against infections caused by mcr-1-positive bacteria,
directly contributing to the development of new effective pharmacotherapies.
